Aktis Oncology, Inc. (AKTS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $20.76: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein... Read more
Sell if holding. Engine safety override at $20.76: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.3/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 59d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Aktis Oncology, Inc.
Latest news
- NEWS Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday — benzinga Jun 12, 2026 positive
- NEWS 12 Health Care Stocks Moving In Tuesday's After-Market Session — benzinga Jun 2, 2026 neutral
- NEWS HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $35 — benzinga Jun 2, 2026 positive
- NEWS Aktis Oncology's AKY-2519 Shows Robust Tumor Uptake And Favorable Dosimetry Across Solid Tumors In First-In-Human B7-H3 — benzinga May 21, 2026 positive
- NEWS Aktis Oncology Q1 EPS $(0.38) Beats $(0.44) Estimate, Sales $3.227M Beat $1.750M Estimate — benzinga May 11, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·2 ceiling hits
Volatile — 8.0% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.76: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $19.31. Score 6.3/10, moderate confidence.
Take-profit target: $28.41 (+36.8% upside). Prior stop was $19.31. Stop-loss: $19.31.
Quality below floor (2.9 < 4.0).
Aktis Oncology, Inc. trades at a P/E of N/A (forward -11.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
12 analysts cover AKTS with a consensus score of 4.3/5. Average price target: $33.
What does Aktis Oncology, Inc. do?Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of...
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.